ArticleCancer reports (Hoboken, N.J.)2026
Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe prognostic impact of the interval between the most recent childbirth and breast cancer diagnosis remains insufficiently defined, particularly when breast cancer diagnosed during pregnancy (PrBC) is distinguished from postpartum breast cancer (PPBC). In this multicenter Chinese cohort, we aimed to validate and extend prior observations regarding the association between time since recent childbirth, clinicopathological features, and outcomes.
methodsThis multicenter retrospective cohort study included 12 453 patients aged 18-55 years with stage I to IV breast cancer for descriptive analyses; stage-restricted sub-cohorts were used for specific survival and modeling analyses as described below. These patients were diagnosed at three hospitals from July 1989 to June 2023, followed up until November 2023. The main exposures were diagnoses during pregnancy or the interval between the most recent childbirth and the diagnoses. The two primary outcomes assessed were disease-free survival (DFS) and breast cancer-specific death (BCSS). Cox proportional hazard models were employed to examine associations between exposures and outcomes. A nomogram using the least absolute shrinkage and selection operator (LASSO) penalty for variable selection. Model performance was evaluated using area under curve (AUC), decision curve analysis (DCA) curves and calibration.
resultsAmong 12 453 patients, 113 (0.9%) were diagnosed during pregnancy and 12 340 after childbirth. Patients diagnosed within 5 years after childbirth showed more aggressive clinicopathological characteristics, including larger tumors, more lymph node metastasis, and a higher Ki67 index. In contrast, results for PrBC should be interpreted cautiously because of the small sample size and potential treatment-related confounding. The poor prognosis of PPBC is potentially linked to an increased risk of liver and brain metastases. Multivariate analysis indicates that a short interval between childbirth and diagnosis is an independent risk factor for breast cancer prognosis. Predictors included in the nomogram were time interval between childbirth and diagnosis of breast cancer, T stage, N stage, and pathological subtype. The AUCs for 1-, 3-, and 5-year DFS prediction were 0.819, 0.767, and 0.731 in the training cohort and 0.818, 0.748, and 0.735 in the validation cohort.
conclusionPatients diagnosed with PPBC within 10 years after their most recent pregnancy, particularly within 5 years, had increased risks of recurrence, metastasis, and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.